- 20 Worst Cars of All Time
- World Wrestling Entertainment (WWE) Stock Jumps Today After Announcing Network Subscriber Milestone
- Advanced Micro Devices (AMD) Stock Continues to Rise Today on Takeover Speculation
- Buy Caterpillar Stock, Collect Its Strong Dividend, Hold for the Long Term
- Advanced Micro Devices (AMD) Stock Spikes Today on Takeover Speculation
Advaxis has seen its shares surge higher in the past month due to increased institutional interest and an optimistic response from investors, said the company's CEO Dan O'Connor.
AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?
Express Scripts CEO George Paz doesn't mince words about the need to cap specialty drug pricing during his talk Tuesday at the J.P. Morgan Healthcare Conference.
Foundation Medicine (FMI) shares are declining today, one session after the stock price doubled.
Aegerion slipped disclosure of the SEC probe into an regulatory filing last night.
Nasdaq’s Head of IPO Listings Bob McCooey says the pipeline for initial public offerings in 2015 is on track to be stronger than what investors saw in 2014.
U.S. markets slipped once again on Monday on falling oil prices. Crude oil fell $2.29 a barrel but settled off its low of the day.
The drop in oil will help discount retailers this earnings season, but it will not give an added lift to luxury players like Tiffany, said JJ Kinahan.
Here's what analysts were saying about Shire's takeover of NPS Pharmaceuticals.
AmerisourceBergen announced on Jan. 12 that it inked a deal to acquire Boise, Idaho-based MWI Veterinary Supply for $2.5 billion.
Foundation Medicine (FMI) shares are rising after Roche Holding (RHHBY) announced that it was purchasing a 56.3% stake in the company.
Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
NPS Pharmaceuticals (NPSP) shares are climbing after the company agreed to be purchased by Shire plc for $5.2 billion.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV